US equities |
MU $983.23 ▲+5.86% META $612.49 ▼-1.24% GOOGL $324.89 ▲+1.34% NVDA $215.38 ▼-1.17% MSFT $531.01 ▼-0.06% TSLA $404.22 ▼-0.80% SPCX $145.23 ▼-2.25% SNDK $1,404.77 ▲+7.66%
FinancialContent

Articles published by Merck & Co., Inc.

< Previous 1 2
...
13 14 15 16 17 18 19 20 Next >
News headline image
Merck Completes Tender Offer to Acquire Imago BioSciences, Inc.
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
News headline image
Merck Named One of America’s Most JUST Companies by JUST Capital and CNBC, Industry Leader in Pharmaceuticals and Biotech
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
News headline image
Merck to Hold Fourth-Quarter and Full-Year 2022 Sales and Earnings Conference Call February 2
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
News headline image
Merck to Present at the 41st Annual J.P. Morgan Healthcare Conference
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
News headline image
Merck to Present at the Goldman Sachs Healthcare CEOs Unscripted Conference
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
News headline image
Merck and Kelun-Biotech Announce Exclusive License and Collaboration Agreement for Seven Investigational Antibody-drug Conjugate Candidates for the Treatment of Cancer
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
News headline image
LYNPARZA® (olaparib) in Combination With Abiraterone and Prednisone or Prednisolone Approved in the EU as Treatment for Certain Patients With Metastatic Castration-Resistant Prostate Cancer
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
News headline image
AstraZeneca and Merck Provide Update on US Regulatory Review of LYNPARZA® (olaparib) in Combination With Abiraterone and Prednisone or Prednisolone as Treatment of Metastatic Castration-Resistant Prostate Cancer
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
News headline image
Merck Begins Tender Offer to Acquire Imago BioSciences, Inc.
From Merck & Co., Inc.
Via Business Wire
Tickers IMGO MRK
News headline image
Merck to Present Data From Its Hematology Portfolio and Promising Pipeline at the 64th American Society of Hematology (ASH) Annual Meeting
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
News headline image
Merck Announces First-Quarter 2023 Dividend
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
News headline image
Merck Announces Phase 3 KEYNOTE-859 Trial Met Primary Endpoint of Overall Survival in Patients With HER2-Negative Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
News headline image
Merck to Present at the 5th Annual Evercore ISI HealthCONx Conference
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
News headline image
Merck to Acquire Imago BioSciences, Inc.
From Merck & Co., Inc.
Via Business Wire
Tickers IMGO MRK
News headline image
LYNPARZA® (olaparib) in Combination With Abiraterone and Prednisone or Prednisolone Receives Positive Opinion From EU CHMP as Treatment for Certain Patients With Metastatic Castration-Resistant Prostate Cancer
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
News headline image
Reductions in Certain Types of HPV-Related Cervical and Non-Cervical Diseases in Women and Men Observed with Real-World Use of Merck's GARDASIL® in Systematic Literature Review of 138 Studies
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
News headline image
Merck Announces Third-Quarter 2022 Financial Results
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
News headline image
Robert M. Davis to Succeed Kenneth C. Frazier as Chairman of Merck
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
News headline image
European Commission Expands Merck’s VAXNEUVANCE™ (Pneumococcal 15-valent Conjugate Vaccine) Indication to Include Infants, Children and Adolescents
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
News headline image
Merck’s PREVYMIS™ Demonstrates Efficacy in Phase 3 Study for Prevention of Cytomegalovirus Disease in Adults After Kidney Transplantation
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
News headline image
Merck and the Bill & Melinda Gates Medical Research Institute Announce Licensing Agreement for Novel Tuberculosis Antibiotic Candidates
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
News headline image
Merck Recognized on Fortune’s 2022 Change the World List for Expanding Access to HPV Vaccines
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
News headline image
Merck Announces Positive Top-line Results from Pivotal Phase 3 STELLAR Trial Evaluating Sotatercept for the Treatment of Adults with Pulmonary Arterial Hypertension (PAH)
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
News headline image
Merck and Ridgeback Biotherapeutics Provide Update on New Clinical and Non-Clinical Studies of LAGEVRIO™ (molnupiravir)
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
News headline image
U.S. Court of Appeals for the Federal Circuit Rules in Favor of Merck in Sitagliptin Dihydrogen Phosphate Patent Lawsuit
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
News headline image
Merck to Hold Third-Quarter 2022 Sales and Earnings Conference Call October 27
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
News headline image
Merck Animal Health Completes Minority Investment in LeeO Precision Farming
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
News headline image
Merck’s KEYTRUDA® (pembrolizumab) Receives Four New Approvals in Japan, Including in High-Risk Early-Stage Triple-Negative Breast Cancer (TNBC)
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
News headline image
Merck Animal Health to Acquire Vence
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
News headline image
LYNPARZA® (olaparib) Approved in China as First-Line Maintenance Treatment With Bevacizumab for Homologous Recombination Deficient (HRD)-Positive Advanced Ovarian Cancer
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
< Previous 1 2
...
13 14 15 16 17 18 19 20 Next >